- Home
- CRGX vs MPB Comparison
CRGX vs MPB Comparison
Compare CRGX & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- MPB
- Stock Information
- Founded
- CRGX 2021
- MPB 1868
- Country
- CRGX United States
- MPB United States
- Employees
- CRGX N/A
- MPB N/A
- Industry
- CRGX
- MPB Major Banks
- Sector
- CRGX
- MPB Finance
- Exchange
- CRGX Nasdaq
- MPB Nasdaq
- Market Cap
- CRGX 190.0M
- MPB 641.4M
- IPO Year
- CRGX 2023
- MPB N/A
- Fundamental
- Price
- CRGX $4.46
- MPB $30.22
- Analyst Decision
- CRGX Hold
- MPB Buy
- Analyst Count
- CRGX 7
- MPB 2
- Target Price
- CRGX $4.67
- MPB $36.00
- AVG Volume (30 Days)
- CRGX 502.9K
- MPB 100.5K
- Earning Date
- CRGX 08-11-2025
- MPB 07-23-2025
- Dividend Yield
- CRGX N/A
- MPB 2.65%
- EPS Growth
- CRGX N/A
- MPB 23.94
- EPS
- CRGX N/A
- MPB 2.88
- Revenue
- CRGX N/A
- MPB $181,865,000.00
- Revenue This Year
- CRGX $57.81
- MPB $24.31
- Revenue Next Year
- CRGX N/A
- MPB $13.74
- P/E Ratio
- CRGX N/A
- MPB $10.50
- Revenue Growth
- CRGX N/A
- MPB 9.21
- 52 Week Low
- CRGX $3.00
- MPB $21.11
- 52 Week High
- CRGX $25.45
- MPB $33.87
- Technical
- Relative Strength Index (RSI)
- CRGX 57.89
- MPB 76.73
- Support Level
- CRGX $4.09
- MPB $28.02
- Resistance Level
- CRGX $4.51
- MPB $28.48
- Average True Range (ATR)
- CRGX 0.18
- MPB 0.62
- MACD
- CRGX 0.00
- MPB 0.35
- Stochastic Oscillator
- CRGX 77.18
- MPB 99.52
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.